Andrew J. Ritter
CIK: 0001631671
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
GTBP
GT Biopharma, Inc.
Director
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Ritter Andrew J
Ritter Andrew J (SEC CIK 0001631671) files insider reports with the SEC as Director of GT Biopharma, Inc. (GTBP).
Signal8 holds 1 ownership filing by Ritter Andrew J, a Form 3, filed on May 29, 2025. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Ritter Andrew J's filings is in SAN FRANCISCO, CA.
Other insiders filing for GT Biopharma, Inc. (GTBP)
- Mun-Gavin David C., Director
- Breen Michael Martin, CEO and Director
- URBAN ALAN LOUIS, Chief Financial Officer
- CASAMENTO CHARLES J, Director
- Kramer Hilary, Director